About Me
I am a clinical professor of psychiatry and child & adolescent psychiatry at the NYU Grossman School of Medicine, associate director of the NYU Langone (CPM), and director of CPM’s research training program. I was first drawn to pursue addiction fellowship training at NYU Langone, inspired by the experience of members of my family and the mission of Bellevue Hospital. I have worked at NYU Langone over the past 25 years in a variety of leadership roles in clinical care, education, and research.
I received my undergraduate degree from the University of Pennsylvania, graduating Phi Beta Kappa, summa cum laude, and majoring in the biological basis of behavior. I received my medical degree from the UCLA School of Medicine, completed residency in general psychiatry at Columbia University/New York State Psychiatric Institute, and fellowship in addiction psychiatry at New York University/Bellevue Hospital.
I am a clinician at heart and went into medicine and psychiatry to take care of patients. I have been a practicing clinical psychiatrist for the past 25 years with a focus on addiction psychiatry, psychotherapy, and psychopharmacology. I have been involved in clinical leadership for most of my time at NYU Langone, including serving as unit chief of the Bellevue Dual Diagnosis Training Unit for five years, director of the Division of Alcoholism and Drug Abuse at Bellevue Hospital for 12 years, and director of the Division of Addiction Psychiatry at NYU Langone’s Tisch Hospital for seven years. I am currently an attending psychiatrist at Bellevue Hospital and Tisch Hospital, as well as a member of the NYU Langone Face Transplant Program, providing psychiatric consultation.
I have been an educator for the entirety of my career, with a focus on teaching addiction psychiatry and medicine. I have taught a spectrum of trainees ranging from medical and dental students and general psychiatry residents to fellows undergoing specialized training in addiction, child and adolescent psychiatry, and forensics. I have been involved in educational leadership, including serving 17 years as associate director or director of the NYU Langone Addiction Psychiatry Fellowship. My teaching activities have been recognized internally at NYU Langone and externally, where I have received over a dozen teaching awards spanning a period from 2000 to 2024.
Beyond caring for patients, I am a physician-scientist conducting clinical research at NYU Grossman School of Medicine since 2006. My major research interests have centered on developing novel pharmacologic-psychosocial approaches to treating patients with addictive disorders such as alcohol and opiate use disorders, psychiatric and existential distress associated with advanced cancer, major depressive disorder, post-traumatic stress disorder (PTSD), personality disorders, and chronic pain. My research has been funded by the National Institutes of Health, foundations, and biotech. My focus, and associated publications on therapeutic applications of psilocybin-assisted psychotherapy (PAP), has been internationally recognized, opening up a pathway for novel and breakthrough treatments of PAP for three of the most common and debilitating conditions in medicine: psychiatric and existential distress in advanced cancer or other serious medical illnesses, alcohol use disorder, and major depressive disorder.
Credentials
Positions
- Clinical Professor,
- Clinical Professor,
- Associate Director, NYU Langone Health Center for Psychedelic Medicine
- Director, NYU Langone Health Psychedelic Medicine Research Training Program
Education and Training
- Fellowship, NYU Grossman School of Medicine, Addiction Psychiatry, 2002
- MD from University of California, Los Angeles, 1996
Is this your profile?
Insurance Plans Accepted
Please call the office for information about accepted insurance plans.
Stephen Ross, MD does not accept insurance.
Locations and Appointments
462 First Avenue, New York, NY 10016
Research My Research
Research Summary
Dr. Stephen Ross is a Research Associate Professor in the Departments of Psychiatry and Child and Adolescent Psychiatry at NYU Grossman School of Medicine. Dr. Ross is a founding member of the NYU Psychedelic Research Group and is currently associate director of NYU Langone’s Center for Psychedelic Medicine and director of the Psychedelic Medicine Research Training Program. In 21 years at NYU Langone and NYC Health + Hospitals/Bellevue, Dr. Ross has been involved in a variety of leadership roles in administration, teaching, and research. He previously served as Director of the Division of Alcoholism and Drug Abuse in the Psychiatry Department at Bellevue for 12 years, Director of Addiction Psychiatry at NYU Langone’s Tisch Hospital, Director of the NYU Addiction Psychiatry Fellowship, Director of the Bellevue Inpatient Dual Diagnosis Training Unit, and Director of the Bellevue Opioid Overdose Prevention Program. Dr. Ross has received over a dozen teaching awards at NYU Langone and nationally over the last 21 years. Dr. Ross’s main research interests focus on developing novel pharmacologic-psychosocial approaches to treating addictive disorders, including the intersection between pain and addiction; psychiatric and existential distress associated with advanced or terminal cancer; major depression; PTSD; and personality disorders. Dr. Ross is principal investigator or co-principal investigator on several ongoing and completed psychedelic-focused studies at NYU Langone including a phase II RCT studying the efficacy of psilocybin-assisted psychotherapy in patients with life-threatening cancer-related psychiatric and existential distress, a phase II RCT studying the effects of psilocybin-assisted psychotherapy in alcohol use disorder, a phase I/II controlled trial administering psilocybin to religious professionals, and a phase II RCT of psilocybin treatment for major depressive disorder. Dr. Ross also acts as a co-investigator and study therapist for phase II/III trials of MDMA-assisted psychotherapy for PTSD and is an expert in cannabinoid therapeutics and PI of a NIDA-funded study of CBD administration in patients with chronic radicular pain on chronic opioid therapy.
Academic Contact
Academic office
462 First Avenue
New York, NY 10016
Phone
Research Interests Timeline
Clinical Trials and Research Studies
-
SOAR: Smartphones for Opiate Addiction Recovery
-
A Phase 2b Randomized Double-blind Placebo-controlled Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Âé¶¹ÊÓÆµapp
-
A Phase 3 Randomized Double-Blind Multicenter Study to Evaluate the Efficacy Safety and Tolerability of Psilocybin in Adults with Major Depressive Disorder
Publications
-
Carrithers, Brennan M; Roberts, Daniel E; Weiss, Brandon M; King, Jacob D; Carhart-Harris, Robin L; Gordon, Alexandra R; Pagni, Broc A; Moreau, Miltiadis; Ross, Stephen; Zeifman, Richard J
Neuropharmacology. 2025 Mar 11; 110413
-
Pagni, Broc A; Zeifman, Richard J; Mennenga, Sarah E; Carrithers, Brennan M; Goldway, Noam; Bhatt, Snehal; O'Donnell, Kelley C; Ross, Stephen; Bogenschutz, Michael P
American journal of psychiatry. 2025 Jan 01; 182(1):114-125
-
Kim, Arum; Halton, Barley; Shah, Akash; Seecof, Olivia M; Ross, Stephen
Annals of palliative medicine. 2024 Nov ; 13(6):1490-1501